SCHEMBL21189311

SCHEMBL21189311

O=C(N[C@H]1CCOc2c(C(=O)Nc3ccc(F)c(F)c3)ccc(F)c21)OCC1CCNC1

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 10/20 0.40
CHRM2 P08172 2/20 0.36
CHRM1 P11229 2/20 0.36
BCL9 O00512 1/20 0.36
CTNNB1 P35222 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21189209 0.89 CHRM3 (0.41) CHRM3CHRM2CHRM1BCL9CTNNB1
SCHEMBL19973622 0.88 CHRM1 (0.47) CHRM3CHRM2CHRM1
Hydrochloric Acid SCHEMBL19973889 0.87 CHRM1 (0.46) CHRM3CHRM2CHRM1
SCHEMBL21189366 0.85 CHRM3 (0.39) CHRM3
SCHEMBL21189274 0.84 CHRNB2 (0.38) CHRM3
SCHEMBL21189406 0.84 CHRM2 (0.41) CHRM3CHRM2CHRM1
Hydrochloric Acid SCHEMBL19973591 0.83 CHRM2 (0.40) CHRM3CHRM2CHRM1
SCHEMBL21189309 0.83 CHRM3 (0.39) CHRM3
SCHEMBL21189527 0.82 MAOB (0.42)
SCHEMBL21189392 0.82 MAOB (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS CHRM3 2581/4885CHRM2 4309/4885CHRM1 3277/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS CHRM3 2581/4885CHRM2 4309/4885CHRM1 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.